Skip to Content

Omontys Side Effects

Generic name: peginesatide

Note: This document contains side effect information about peginesatide. Some of the dosage forms listed on this page may not apply to the brand name Omontys.

Applies to peginesatide: injectable solution

Cardiovascular

Cardiovascular side effects have included hypotension (14.2%), hypertension (13.2%), and procedural hypotension (10.9%).[Ref]

Gastrointestinal

Gastrointestinal side effects have included diarrhea (18.4%), nausea (17.4%), and vomiting (15.3%).[Ref]

General

General side effects have included pyrexia (12.2%).[Ref]

Immunologic

Immunologic side effects have included the development of peginesatide (the active ingredient contained in Omontys) specific antibodies (1.2%).[Ref]

Metabolic

Metabolic side effects have included hyperkalemia (11.4%).[Ref]

Musculoskeletal

Musculoskeletal side effects have included muscle spasms (15.3%), pain in extremity (10.9%), back pain (10.9%), and arthralgia (10.7%).[Ref]

Nervous system

Nervous system side effects have included headache (15.4%).[Ref]

Other

Other side effects have included arteriovenous fistula site complication (16.1%).[Ref]

Respiratory

Respiratory side effects have included dyspnea (18.4%), cough (15.9%), and upper respiratory infection (11.0%).[Ref]

Hypersensitivity

Hypersensitivity side effects have included postmarketing reports of serious allergic reactions including fatal reactions (0.02%).

References

1. "Product Information. Omontys (peginesatide)." Takeda Pharmaceuticals America, Lincolnshire, IL.

Medically reviewed by Drugs.com. Last updated on Aug 15, 2020.

More about Omontys (peginesatide)

Consumer resources

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.